SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 3,311 Shares of Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 3,311 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $14.20, for a total transaction of $47,016.20. Following the sale, the chief financial officer owned 211,134 shares in the company, valued at $2,998,102.80. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, August 18th, Anshul Maheshwari sold 3,461 shares of SiBone stock. The stock was sold at an average price of $15.57, for a total transaction of $53,887.77.

SiBone Trading Down 0.1%

NASDAQ SIBN opened at $14.49 on Tuesday. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05. The firm has a 50 day moving average of $15.70 and a two-hundred day moving average of $16.27. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $625.11 million, a PE ratio of -25.87 and a beta of 0.83.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. The business had revenue of $48.63 million during the quarter, compared to analysts’ expectations of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. SiBone has set its FY 2025 guidance at EPS. As a group, research analysts expect that SiBone will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on SIBN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Saturday, September 27th. Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the company an “overweight” rating in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Institutional Trading of SiBone

A number of large investors have recently made changes to their positions in the company. Johnson Investment Counsel Inc. acquired a new position in SiBone during the first quarter worth approximately $148,000. Rhumbline Advisers grew its position in shares of SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after acquiring an additional 2,100 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of SiBone by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock valued at $55,000 after acquiring an additional 3,867 shares during the period. Harbor Capital Advisors Inc. raised its position in SiBone by 7.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 573,705 shares of the company’s stock valued at $10,797,000 after purchasing an additional 40,993 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in SiBone by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after purchasing an additional 83,919 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.